This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Burns  • Alert me on articles by topic  Social Bookmarking   What's this?

Albert T. McManus, PhD; Cleon W. Goodwin, MD; Basil A. Pruitt, Jr, MD

Arch Surg. 1998;133:1207-1211.

Objective  To document the risk of the development of vancomycin-resistant bacteria in a population of seriously burned patients during a 10-year period of common vancomycin hydrochloride use.

Design  Retrospective study.

Setting  The US Army Institute of Surgical Research, Burn Center, Fort Sam Houston, Tex.

Population and Methods  Microbiology, infection, and antibiotic use records collected during the hospitalization of 2266 consecutively admitted seriously burned patients were reviewed. Vancomycin was the primary therapeutic agent used for gram-positive infections and was also used as a perioperative prophylactic antibiotic during burn wound excision. This policy was established prior to this review because of a high incidence of methicillin-resistant Staphylococcus aureus colonization and an anecdotal association of increased -lactam resistance in endemic gram-negative pathogens associated with the use of penicillinase-resistant penicillins and cephalosporins.

Main Outcome Measures  Isolation of vancomycin-resistant enterococci (VRE) or other gram-positive organisms resistant to vancomycin.

Results  Examinations of 15,125 gram-positive isolates, including 957 enterococci, for in vitro sensitivity to vancomycin yielded 3 VRE isolates in 3 patients. Vancomycin was used prior to VRE isolation in one of these patients. Resistance was found in 3 other organisms (2 Corynebacterium species, 1 Lactobacillus species). Vancomycin was used prior to these isolations in 2 of 3 patients. None of the vancomycin-resistant organisms was associated with infection and all 6 patients survived. Vancomycin-resistant enterococci or other vancomycin-resistant gram-positive organisms were not found in 663 patients treated with vancomycin for documented gram-positive infections or in 1027 patients where perioperative vancomycin was used.

Conclusion  Use of vancomycin as the primary therapeutic agent in seriously burned patients was not associated with increased risk of VRE isolation or VRE infection.

From the US Army Institute of Surgical Research, Fort Sam Houston, Tex.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tolerance of Vancomycin for Surgical Prophylaxis in Patients Undergoing Cardiac Surgery and Incidence of Vancomycin-Resistant Enterococcus Colonization
Kachroo et al.
The Annals of Pharmacotherapy 2006;40:381-385.
ABSTRACT | FULL TEXT  

In Vitro Activity and Killing Effect of Uperin 3.6 against Gram-Positive Cocci Isolated from Immunocompromised Patients
Giacometti et al.
Antimicrob. Agents Chemother. 2005;49:3933-3936.
ABSTRACT | FULL TEXT  

Temporin A Soaking in Combination with Intraperitoneal Linezolid Prevents Vascular Graft Infection in a Subcutaneous Rat Pouch Model of Infection with Staphylococcus epidermidis with Intermediate Resistance to Glycopeptides
Giacometti et al.
Antimicrob. Agents Chemother. 2004;48:3162-3164.
ABSTRACT | FULL TEXT  

Prophylactic Efficacy of Topical Temporin A and RNAIII-Inhibiting Peptide in a Subcutaneous Rat Pouch Model of Graft Infection Attributable to Staphylococci With Intermediate Resistance to Glycopeptides
Cirioni et al.
Circulation 2003;108:767-771.
ABSTRACT | FULL TEXT  

Efficacy of Quinupristin-Dalfopristin in Preventing Vascular Graft Infection Due to Staphylococcus epidermidis with Intermediate Resistance to Glycopeptides
Giacometti et al.
Antimicrob. Agents Chemother. 2002;46:2885-2888.
ABSTRACT | FULL TEXT  

Effects of Antibiotics on Nosocomial Epidemiology of Vancomycin-Resistant Enterococci
Harbarth et al.
Antimicrob. Agents Chemother. 2002;46:1619-1628.
FULL TEXT  

Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis
Giacometti et al.
J Antimicrob Chemother 2000;46:751-756.
ABSTRACT | FULL TEXT  

Mupirocin Prophylaxis against Methicillin-Susceptible, Methicillin-Resistant, or Vancomycin-Intermediate Staphylococcus epidermidis Vascular-Graft Infection
Giacometti et al.
Antimicrob. Agents Chemother. 2000;44:2842-2844.
ABSTRACT | FULL TEXT